The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base

Cancer

Volumn 120, Issue 14, 2014, Pages 2114-2121

  Martin, Jeffrey M ^a   Handorf, Elizabeth A ^a   Kutikov, Alexander ^a   Uzzo, Robert G ^a   Bekelman, Justin E ^b   Horwitz, Eric M ^a   Smaldone, Marc C ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

brachytherapy; clinical practice patterns; prostatectomy; prostatic neoplasms; radiotherapy; use

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER REGISTRY; COMORBIDITY; CONTROLLED STUDY; DATA BASE; HEALTH CARE POLICY; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICARE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; TREND STUDY; CLINICAL PRACTICE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; EDUCATIONAL STATUS; EPIDEMIOLOGY; ETHNOLOGY; FACTUAL DATABASE; HEALTH INSURANCE; INCOME; MIDDLE AGED; PATHOLOGY; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGISTER; RURAL POPULATION; STATISTICS AND NUMERICAL DATA; SUBURBAN POPULATION; TRENDS; UNITED STATES; URBAN POPULATION; UTILIZATION; UTILIZATION REVIEW; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COHORT STUDIES; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; EDUCATIONAL STATUS; HUMANS; INCOME; INSURANCE, HEALTH; MALE; MEDICARE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGISTRIES; RURAL POPULATION; SUBURBAN POPULATION; UNITED STATES; URBAN POPULATION; UTILIZATION REVIEW;

EID: 84903783072     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28697     Document Type: Article

References (29)

1. Hayes JH, Ollendorf DA, Pearson SD, et al. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med. 2013; 158: 853-860.
2. Holm HH, Juul N, Pedersen JF, Hansen H, Stroyer I,. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol. 1983; 130: 283-286. (Pubitemid 13037600)
3. Mettlin CJ, Murphy GP, McDonald CJ, Menck HR,. The National Cancer Data base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S. Cancer. 1999; 86: 1877-1882. (Pubitemid 29513059)
4. Jani AB, Johnstone PA, Liauw SL, Master VA, Rossi PJ,. Prostate cancer modality time trend analyses from 1973 to 2004: a Surveillance, Epidemiology, and End Results registry analysis. Am J Clin Oncol. 2010; 33: 168-172.
5. Iglehart JK,. Prioritizing comparative-effectiveness research-IOM recommendations. N Engl J Med. 2009; 361: 325-328.
6. Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013; 105: 25-32.
7. Jacobs BL, Zhang Y, Schroeck FR, et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013; 309: 2587-2595.
8. Bilimoria KY, Stewart AK, Winchester DP, Ko CY,. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008; 15: 683-690.
9. National Comprehensive Cancer Network. Prostate Cancer V1. 2014 http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf. Accessed on March 20, 2014.
10. Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013; 64: 895-902.
11. Liang KY, Zeger SL,. Longitudinal data-analysis using generalized linear-models. Biometrika. 1986; 73: 13-22.
12. Mahmood U, Pugh T, Frank S, et al. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. 2014; 13: 157-162.
13. Stitzenberg KB, Wong YN, Nielsen ME, Egleston BL, Uzzo RG,. Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer. 2012; 118: 54-62.
14. Lowrance WT, Eastham JA, Savage C, et al. Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol. 2012; 187: 2087-2092.
15. Barbash GI, Glied SA,. New technology and health care costs-the case of robot-assisted surgery. N Engl J Med. 2010; 363: 701-704.
16. Abbou CC, Hoznek A, Salomon L, et al. Laparoscopic radical prostatectomy with a remote controlled robot. J Urol. 2001; 165: 1964-1966.
17. Addressing the evidence gap-randomized controlled trials for the surgical management of localized genitourinary tract malignancies. Urol Oncol. 2013; 31: 393-397.
18. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013; 368: 436-445.
19. Loeb S, Berglund A, Stattin P,. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol. 2013; 190: 1742-1749.
20. Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012; 109 (suppl 1): 22-29.
21. Sylvester JE, Grimm PD, Wong J, Galbreath RW, Merrick G, Blasko JC,. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys. 2011; 81: 376-381.
22. Taira AV, Merrick GS, Butler WM, et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2011; 79: 1336-1342.
23. Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007; 109: 518-527. (Pubitemid 46190959)
24. Cooperberg MR, Ramakrishna NR, Duff SB, et al. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013; 111: 437-450.
25. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011; 29: 1517-1524.
26. Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY,. Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol. 2009; 27: 4177-4181.
27. Rosenbaum L,. The whole ball game-overcoming the blind spots in health care reform. N Engl J Med. 2013; 368: 959-962.
28. Shah C, Lanni TB Jr, Ghilezan MI, et al. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy. 2012; 11: 441-445.
29. Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP,. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer. 2012; 118: 3512-3518.